Company intelligence / Profile preview
CHIGENOVO
Beijing, Beijing Shi, Chinachinagene.cc ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
ZVS-101e is in Phase 3 for Bietti Crystalline Dystrophy, and ZVS-106e is in Preclinical stage for Stargardt Disease. Both ZVS101e and ZVS203e have orphan drug designations granted by FDA.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapyAAV based gene therapyGene editing
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on CHIGENOVO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHIGENOVO.